ClinicalTrials.gg
Active, not recruitingNCT04657432Updated Apr 2, 2026

Brief, High-dose rTMS for Depression

An interventional study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depression and Anxiety, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Depression by Medical University of South Carolina — 17 open to participants now, 21 under way, none of them phase 3. Depression · Medical University of South Carolina.

Planned enrollment
17th of 45
70 · median 46
Started
2021
with 3 others
No phase
31 of 47
13 open now
Primary completion
2026-12
later than 3 of 20 live
Registered
25th of 47
by date

Among the 47 studies in Depression by Medical University of South Carolina, this one is the 17th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 with no phase, reaches primary completion later than 3 of the 20 other live ones, and was the 25th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

17 of the 47 studies in Depression by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Depression by Medical University of South Carolina, or all of them as a file.
02

Study summary

High frequency repetitive transcranial magnetic stimulation (rTMS) has been shown to be safe, feasible, and acceptable. Conventionally, rTMS investigations have relied on rational decision trees for dosage determination. The purpose of this study is to systematically examine an accelerated protocol of intermittent theta burst (iTBS). Study 1 aims to provide a quantifiable dose-response curve for iTBS and depressive symptom reduction in major depression. Study 2 aims to determine the role of individual variations of their functional networks compared to the site of stimulation and clinical outcomes.

03

Conditions studied

  • Depression
  • Anxiety
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A negative urine pregnancy test, if female subject of .
  • Able to speak English and complete study forms, adhere to treatment regimens, and be willing to return for regular visits.
  • After full explanation of the study, willingness of participant is demonstrated by signing the form.

Exclusion criteria

Exclusion Criteria:

  • Clinically unstable medical disease:

    • cardiovascular
    • renal
    • gastrointestinal
    • pulmonary
    • metabolic
    • endocrine
    • other
  • CNS disease deemed progressive
  • Moderate or severe traumatic brain injury (TBI)
  • Pregnant females or those currently breast-feeding.
  • Current or history of schizophrenia or other psychotic disorder, except psychosis not otherwise specified (NOS) when the presence of sensory hallucinations is clearly related to the subject's trauma, Bipolar Type I disorder, or dementia:

    • vascular
    • Alzheimer's disease
    • other types
  • Repeated abuse or dependence upon drugs (excluding nicotine and caffeine) within 6 days of study entry, with the exception of alcohol use disorder, which, at the discretion of the study team, may be permitted.

See further explanation under protection from risk.

  • Active participation or plan for enrollment in another evidence-based psychotherapeutic clinical trial
  • Participation in other psychotherapeutic modalities must have been stable for 3 months prior to enrollment and must remain stable throughout participation.
  • Currently taking medications that have short half-lives, lower the seizure threshold, and do not have evidence of antidepressant efficacy. These include:

    • high dose theophylline or stimulants such as methylphenidate patients taking bupropion must be on a stable dose and take less than or equal to 300 mg/day. Stable means the same dose for 5 half-lives.
  • An implanted device in subject's head (shunt, cochlear implant) and/or metal in subject's head (other than dental implant).
  • History of seizures or a seizure disorder.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Dose 1

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 2

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 3

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 4

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 5

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 6

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 7

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 8

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 9

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Dose 10

    All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    Study 2: 10 Active Doses

    All participants will be assigned to 10 sessions (per treatment day) of accelerated rTMS for 5 treatment days. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 active sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation (rTMS)

    MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

06

What researchers measure

Primary outcomes

  1. Depression severity (change in score)

    Depression severity as assessed by: 1\. Hamilton Scale for Depression (HAM-D) Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. 10 - 13 mild; 14-17 mild to moderate; \>17 moderate to severe.

    Time frame: Day 1, post-treatment point of 1 month

  2. Depression severity (change in score)

    Depression severity as assessed by: 2\. Montgomery-Asberg Depression Rating Scale (MADRS) Rating lies on the defined scale steps (0, 2, 4, 6) or between them (1, 3, 5). Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.

    Time frame: Day 1, post-treatment point of 1 month

  3. Depression severity (change in score)

    Depression severity as assessed by: 3\. Beck Depression Inventory-II (BDI-II) Rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.

    Time frame: Day 1, post-treatment point of 1 month

Secondary outcomes

  1. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 1\. Inventory of Depression and Anxious Symptoms (IDAS-II) -Questions are rated on a scale from 1-5 and covers a wide array of psychological measures

    Time frame: Day 1, post-treatment point of 1 month

  2. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 2\. Mood and Anxiety Symptom Questionnaire -Questions designed to assess symptoms of general distress using a 5-point Likert scale ranging from 1"not at all" to 5 "extremely".

    Time frame: Day 1, post-treatment point of 1 month

  3. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 3\. Penn State Worry Questionnaire -Questions are rated on a scale from: 1-Not at all typical of me to 5-Very typical of me. Possible range of scores is 16-80 with the algorithm of Total scores: 16-39 Low Worry, 40-59 Moderate Worry, and 60-80 High Worry

    Time frame: Day 1, post-treatment point of 1 month

  4. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 4\. PTSD Checklist (PCL-5) The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The PCL-5 has a variety of purposes, including: Monitoring symptom change during and after treatment Screening individuals for PTSD Making a provisional PTSD diagnosis -Questions are rated on a 5-point Likert scale (0 = "Not at all" to 4 = "Extremely")

    Time frame: Day 1, post-treatment point of 1 month

  5. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 5\. Life Events Checklist (LEC-5) The Life Events Checklist for DSM-5 (LEC-5) is a self-report measure designed to screen for potentially traumatic events in a respondent's lifetime. The LEC-5 assesses exposure to 16 events known to potentially result in PTSD or distress and includes one additional item assessing any other extraordinarily stressful event not captured in the first 16 items. -Responses are as followed: Happened to me; Witnessed it; Learned about it; Part of my job; Not sure; Doesn't apply

    Time frame: Day 1, post-treatment point of 1 month

  6. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 6\. Childhood Trauma Questionnaire -The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.

    Time frame: Day 1, post-treatment point of 1 month

  7. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 7\. Fagerstrom Test for Nicotine Dependence -Yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.

    Time frame: Day 1, post-treatment point of 1 month

  8. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 8\. Alcohol Use Disorders Identification Test (AUDIT) -The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems.

    Time frame: Day 1, post-treatment point of 1 month

  9. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 9\. World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) -Questions are rated on a a 5 point scale (from 0-4) Likert scale

    Time frame: Day 1, post-treatment point of 1 month

  10. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 10\. World Health Organization Quality of Life - Brief Form (WHOQOL-BF) -Questions are rated on a a 5 point scale (from 1-5) Likert scale

    Time frame: Day 1, post-treatment point of 1 month

  11. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 11\. Illness Intrusive Rating Scale (IIRS) -Questions are rated on a a 7 point scale (from 1-7) Likert scale which is a measure of the psychosocial impact of chronic disease

    Time frame: Day 1, post-treatment point of 1 month

  12. Comorbid symptom severity, functional impairment, acceptability, and tolerability

    Participants would complete various questionnaires (change in score assessed): 12\. Quality of Life and Enjoyment and Satisfaction Questionnaire -Short Form (Q-LES-Q-SF) -Questions are rated on a 5 point scale (from 1-5) Likert scale. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70.

    Time frame: Day 1, post-treatment point of 1 month

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 66 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
May 25, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04657432
Collaborators
National Alliance for Research on Schizophrenia and Depression
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
May 25, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion